CARB-X is fully committed to addressing the global health threat of antimicrobial resistance. This week, its leaders convened at the ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance to lay the groundwork for CARB-X’s next decade, including plans to strengthen international collaboration and support, and to launch new funding rounds for product developers.

    Full Story

  • 10.03.2022  |  CARB-X launches new funding rounds for critical global health needs

    CARB-X seeks preventatives, diagnostics and therapeutics that address neonatal sepsis, gonorrhea and the most threatening antimicrobial-resistant bacterial infections.

    Full Story

  • 07.08.2022  |  GARDP and CARB-X welcome renewed commitment by G7 leaders to address antimicrobial resistance

    The Global Antibiotic Research and Development Partnership (GARDP) and Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) jointly welcome the recent G7 Leaders’ Communiqué, which acknowledges the rapid rise in antimicrobial resistance (AMR) globally and renews the commitment by G7 governments to address the most dangerous drug-resistant infections.

    Full Story

  • 06.16.2022  |  CARB-X expands international reach with appointment of Damiano de Felice as Director of Development and External Engagement

    CARB-X announced the appointment of Damiano de Felice, PhD, as Director of Development and External Engagement to the senior executive team. Dr. de Felice will manage CARB-X’s relationships with funders, investors in product developers and other organizations working to address antimicrobial resistance. He will also be responsible for the development of CARB-X’s financial sustainability strategy.

    Full Story

  • 05.19.2022  |  U.S. government and Wellcome commit up to an additional US$370 million to CARB-X

    After celebrating its five-year anniversary in 2021, CARB-X (part of Boston University) announces renewed support from the U.S. Department of Health and Human Services (HHS) and Wellcome Trust, a U.K.-based global charitable foundation. The Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within HHS, will provide US$20 million initially and up to US$300 million over 10 years to support the existing portfolio and launch new funding rounds. Wellcome will provide up to US$70 million over three years as part of its continued commitment to address the escalating threat of drug-resistant infections. Initial funding of $355 million from both BARDA and Wellcome originally launched CARB-X in 2016, and the new funding announced today builds on the success of this international non-profit partnership.

    Full Story